Cyanotic congenital heart disease
Conditions
Interventions
experimental group:Continuous infusion of esmolol at 25-50ug / kg / min
Sponsors
Shanghai Children's Medical Center
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: From June 2020 to June 2023, all children with cyanotic congenital heart disease (0-18 years old) undergoing cardiopulmonary bypass were included. The disease types included: tetralogy of Fallot, double outlet of right ventricle, transposition of great arteries, pulmonary atresia and permanent arterial trunk. Patients were randomly divided into esmolol treatment group (T Group) and blank normal saline control group (NS group). According to preoperation oxygen saturation, patients were divided into three subgroups, 90% and above, 70% - 89%, 70% and below. The random number table was generated by computer, and the drug allocation was carried out by GCP nurses. The unified anesthesia manager was single blind to the study drug.
Exclusion criteria
Exclusion criteria: Liver, kidney and brain dysfunction; patients to be palliative surgery; allergic to the study drug.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CI;MBP;SpO2;CKMB;cTnI;HR;LAC;Pca-vCO2; | — |
Countries
China
Contacts
Public ContactYunan Song
Shanghai Children's Medical Center
Outcome results
None listed